Sanofi Pompe Drug Shortage Leaves Patients in Limbo as Supply Disruption Persists

Sanofi Pompe Drug Shortage Leaves Patients in Limbo as Supply Disruption Persists

A supply disruption for critical treatments of Pompe disease persists, leaving many patients with canceled infusions and growing anxiety about their health. More than three months after initial reports of the shortage, Sanofi has confirmed that shipping delays may continue to affect some U.S. patients through the end of November. While the French pharmaceutical company stated it is making progress in restoring supply in certain countries, the ongoing gap in medication access has left individuals like Monique Griffin, a 51-year-old wheelchair user diagnosed with the rare muscle-wasting condition, fearing a resurgence of symptoms.

Griffin, who relies on Sanofi’s Lumizyme and its second-generation version, Nexviazyme, to manage her disease, received an email two weeks ago notifying her that her next infusion had been canceled. “It’s terrifying,” she said, describing the situation as the disease potentially taking over again. Pompe disease, which affects approximately one in every 19,000 newborns, involves a lack of an enzyme needed to break down glycogen. Without treatment, the resulting toxic buildup can weaken muscles, enlarge the heart, and impair breathing and eating, often leading to fatal outcomes if left untreated.

Sanofi attributed the shortage to ongoing issues at its manufacturing facility in Ireland. Public records indicate the company has been aware of these problems for months. The U.S. Food and Drug Administration inspected the plant in January 2026 and issued a warning letter in June regarding violations of manufacturing requirements. A Sanofi spokesman emphasized that there were no issues with drug quality and that the company is prioritizing the most vulnerable patients during this period. However, he warned that the medicines are not interchangeable, advising patients to consult healthcare professionals before considering alternative treatments.

The FDA has stated that ensuring patient access to these therapies is a priority and has offered assistance to Sanofi to meet all patient needs. Meanwhile, frustration has mounted within the Pompe disease community over what advocates describe as a lack of proactive transparency. Ryan Colburn, a patient and advocate, noted that many individuals were unaware of the manufacturing issues and had no way to prepare for potential disruptions. Chelsey McGee, a mother in Minneapolis, expressed similar concerns for her 10-year-old son, who has been on a regular infusion schedule since infancy. McGee discovered the FDA citations through public records rather than from the company, highlighting the opacity surrounding the supply chain issues. While alternative therapies, such as gene therapies from AskBio and Astellas Pharma, are in clinical trials, current patients rely heavily on Sanofi’s biannual treatments to maintain their quality of life.

9 responses to “Sanofi Pompe Drug Shortage Leaves Patients in Limbo as Supply Disruption Persists”

  1. Three months is an eternity. My mother’s heart condition is worsening fast. They need a real timeline, not just promises.

  2. Gene therapies sound promising but years away. What about the thousands needing help right now? This is a crisis.

  3. I checked the FDA database myself and found the warning letter. Why is the company hiding this from patients directly?

  4. My son depends on these infusions. Seeing the supply chain fail is horrifying and completely irresponsible for a big pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *